Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247309 · ClinicalTrials.gov registry record · Phase 1
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
A Phase 1 study of Cancer and Solid Tumor, sponsored by Immatics US.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT03247309 is a Phase 1 study of Cancer and Solid Tumor that has completed, run by Immatics US. The registered enrollment target is 7 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03247309, a Phase 1 study of Cancer and Solid Tumor, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
Conditions Studied
Interventions
- BIOLOGICAL IMA201 Product
- DIAGNOSTIC_TEST IMADetect®
Study Locations (5)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- University of Texas MD Anderson Cancer Center - Houston
North Rhine-Westphalia
- Universitätsklinikum Bonn, Venusberg-Campus 1 - Bonn
Saxony
- Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74 - Dresden
Other
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03247309
The ClinicalTrials.gov registry entry for NCT03247309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which IMA201 Product is the first listed.
NCT03247309 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, Texas, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT03247309 about?
NCT03247309 is a clinical study titled "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)". The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
What is the current status of trial NCT03247309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-12-19. Estimated completion is 2023-09-18.
What conditions does trial NCT03247309 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Refractory Solid Tumors, Recurrent Solid Tumors.
What interventions are being tested in trial NCT03247309?
The interventions under investigation include: IMA201 Product (BIOLOGICAL), IMADetect® (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03247309?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03247309 being conducted?
This trial has 5 study locations across Pennsylvania, Texas, North Rhine-Westphalia, Saxony. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.